Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

PURPOSE: The monoclonal antibody fremanezumab has been shown effective and well tolerated in numerous Phase 2 and Phase 3 trials. This subgroup analysis of the international HALO episodic migraine (EM; [NCT02629861]) trial and a similarly designed phase 2b/3 trial in Japanese and Korean patients (NC...

Descripción completa

Detalles Bibliográficos
Autores principales: Saigoh, Kazumasa, Takeshima, Takao, Nakai, Masami, Shibasaki, Yoshiyuki, Ishida, Miki, Ning, Xiaoping, Barash, Steve, Isogai, Yuki, Koga, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202207/
https://www.ncbi.nlm.nih.gov/pubmed/37223438
http://dx.doi.org/10.2147/JPR.S393896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202207/
https://www.ncbi.nlm.nih.gov/pubmed/37223438
http://dx.doi.org/10.2147/JPR.S393896

Ejemplares similares